{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"PD-1 expression and leukocyte activation markers on circulating lymphocytes pre-treatment, at weeks 3 and 6, and at time of disease progression","groups":[{"description":"MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles\n\nMK-3475","id":"OG000","title":"Treatment"},{"description":"MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study\n\nMK-3475\n\nCopanlisib","id":"OG001","title":"Combination"}],"populationDescription":"Data was not collected as the trial was halted early after a preplanned interim futility analysis","reportingStatus":"POSTED","timeFrame":"Week 3","title":"PD-1 Expression and Leukocyte Activation Markers on Circulating Lymphocytes Pre-treatment","type":"OTHER_PRE_SPECIFIED"}